I t is well documented that certain long-chain polyunsaturated fatty acids (PUFAs), such as the omega-3s (n3) in fatty fish, are beneficial with respect to cardiovascular health. More recently, it has been proposed that the omega6 (n6) PUFAs may also have health benefits 1-4 although opposing findings have also been reported. 5-7 N6 PUFAs metabolize into the powerful bioactive eicosanoids, such as leukotrienes, thromboxanes, and lipoxins, that influence biological processes that relate to health, such as inflammation and platelet aggregation. N6 PUFAs have been differentially associated with inflammatory cytokines, clotting factors, and endothelial dysfunction markers, but only for certain n6 PUFAs. [8] [9] [10] Because plasma and cell membranes may be composed of different n6 PUFAs in variable concentrations, it is important to characterize the determinants of plasma and cell membrane n6 PUFA composition. Dietary intake, lifestyle, and demographic characteristics 11-15 are well known to influence n6 levels; however, recent findings from genome-wide association studies (GWAS) and the Kibbutzim Family Study indicate a strong genetic component in determining plasma and erythrocyte fatty acid composition. [16] [17] [18] 
acid desaturase (FADS) genes, FADS1 and FADS2. These biologically relevant candidate genes encode the δ-5 and δ-6 desaturases, which participate in the metabolic conversion of the essential fatty acid linoleic acid (LA) to longer chain n6 PUFAs (Figure 1) . Candidate gene studies have demonstrated significant associations of the minor alleles in the FADS cluster with multiple n6 PUFAs, including arachidonic acid (AA; 20:4n6), LA (18:2n6), γ-LA (GLA; 18:3n6), dihomo-γ-LA (DGLA; 20:3n6), and adrenic acid (AdrA; 22:4n6). [19] [20] [21] [22] A recent GWAS of fatty acids confirmed the association of genetic variants in FADS1, FADS2, and FADS3 with LA and AA 18 ; however, it remains unknown whether other loci beyond FADS influence LA and AA composition, and whether any genetic loci influence levels of the other n6 fatty acids, including GLA, DGLA, and AdrA.
Given the gaps in our current knowledge of genetic determinants of n6 PUFA composition, we performed a largescale meta-analysis of GWAS from 5 participating cohorts in the Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium 23 to identify common genetic variants associated with plasma n6 fatty acid phenotypes, including LA, GLA, DGLA, AA, and AdrA.
Materials and Methods

Ethics Statement
Informed consent forms were signed by participants, and each local institutional review board of the participating cohort studies approved the study protocols.
Study Population
Study participants in the current GWAS were of European ancestry, had available plasma n6 PUFA and genetic data, and were enrolled in 1 of 5 cohorts, including the Atherosclerosis Risk in Communities (ARIC) study (n=3269), Coronary Artery Risk Development in Young Adults (CARDIA) study (n=1507), Cardiovascular Health Study (CHS; n=2404), Invecchiare in Chianti (InCHIANTI) study (n=1075), and an ancillary study to the Multi-Ethnic Study of Atherosclerosis (MESA; n=707). Descriptions of each of these studies have been previously published. [24] [25] [26] [27] [28] 
Measurement of Plasma Phospholipid or Total Plasma Fatty acids
Details of plasma fatty acid measurement have been described previously (Data Supplement). In the ARIC, CARDIA, and MESA cohorts, phospholipid fatty acids were analyzed according to Cao et al. 29 First, total lipids were extracted, and phospholipid fraction was isolated by thin layer chromatography. Isolated phospholipids were then converted to fatty acid methyl esters for further separation by gas chromatography. CHS used a similar method (Data Supplement). In the InCHIANTI study, total plasma fatty acids were directly measured by gas chromatography. 30 AdrA was measured in the ARIC and CHS cohorts only. N6 fatty acids in all studies were expressed as percentage of total fatty acids.
Imputation and Statistical Analysis
Genotyping was done in each cohort separately using high-density single-nucleotide polymorphism (SNP) marker platforms (ARIC, CARDIA, and MESA: Affymetrix 6.0; CHS: Illumina 370; InCHIANTI: Illumina 550). Samples with call rates below 95% (ARIC, CARDIA, and MESA) or 97% (CHS and InCHIANTI) at genotyped markers were excluded. Genotypes were imputed to ≈2.5 million HapMap SNPs using MACH 31 (ARIC and InCHIANTI), BIMBAM 32 (CHS), BEAGLE 33 (CARDIA), or IMPUTE2.1.0 34 (MESA). SNPs for which testing Hardy-Weinberg equilibrium resulted in P<10 -5 were excluded from imputation. SNPs with minor allele frequency <1% or imputation quality score (estimated r 2 ) <0.3 were excluded from the meta-analyses. Additional details on genotyping and imputation per cohort are provided in Table I in the Data Supplement.
The main analysis was linear regression of each fatty acid on single-SNP allele dosage from imputation, including covariates to account for age, sex, site of recruitment when appropriate (InCHIANTI, CARDIA, CHS, and MESA), as well as the top 2 (MESA) or top 10 (CARDIA and CHS) principal components to adjust for potential population structure. To reduce the complexity of analysis by each cohort, we chose a conservative model without adjusting for diet and other lifestyle variables. In all cohorts, we used a robust Huber-White sandwich variance estimator, which provides protection against missspecified mean models, as well as nonconstant variance (heteroskedasticity). [35] [36] [37] The association results in each cohort were corrected by genomic control method, 38 which provides additional protection against spurious findings because of population stratification; the results were then combined using inverse-variance-weighted meta-analysis in METAL (www.sph.umich.edu/csg/abecasis/metal). Cochran Q test was used to assess potential heterogeneity among results from multiple cohorts. 39 As the Cochran Q test P value for each meta-analysis in our study was ≥0.05, we chose the fixed effect metaanalysis to pool results across the cohorts. We declared a fatty acid-SNP association genome-wide significant if the nominal P value for the SNP was <5×10 -8 . For the significantly associated SNPs, we calculated the proportion of variation explained by a particular variant in each cohort using an approximation: (β 2 ×2×minor allele frequency ×(1−minor allele frequency))/Var(Y), where β is the regression coefficient for 1 copy of the allele and Var(Y) is the variance of the fatty acid in the corresponding cohort.
To explore additional independent susceptibility variants at the loci identified in the main analysis, we repeated the GWAS and metaanalysis conditioning on the most significant SNPs in each loci, specifically rs10740118 (chromosome 10), rs174547 (chromosome 11), and rs16966952 (chromosome 16).
We also performed GWAS and meta-analysis in which each SNP was tested for association with n6 fatty acid levels, adjusting for levels of the preceding fatty acid in the biological pathway ( Figure 1 ). For example, to identify additional SNPs associated with GLA (18:3n6), we conducted a GWAS of GLA with adjustment for LA (18:2n6).
Results
The 5 cohort studies included 8631 adults (55% women) of European ancestry, who were average age 60 years ( Table 1 ). The mean proportion of LA in plasma phospholipids was ≈20% of total phospholipid fatty acids, ranging from 19.96% in CHS to 21.98% in CARDIA. The mean proportion of AA ranged from 10.87% in CHS to 12.1% in MESA. InCHIANTI, total plasma LA was slightly higher (24.78%) and AA was lower (8.00%), relative to the phospholipid fatty acid fraction in other cohorts. 8 GLA and DGLA were present in substantially smaller amounts across studies (range, 0.09%-0.12% and 3.13%-3.33%, respectively). In ARIC and CHS, plasma phospholipid fatty acids were analyzed for AdrA and the proportions were similar in the 2 studies. Figure 2A to 2E shows the Manhattan plots for the metaanalysis of the GWAS results for LA, AA, GLA, DGLA, and AdrA. The genomic inflation factors are 1.02, 0.99, 1.01, 1.02, and 1.02 for LA, GLA, DGLA, AA, and AdrA, respectively. For the primary analysis, adjusting for only age and sex (and other covariates where applicable), genome-wide significant signals were identified on chromosomes 10, 11, and 16 for LA, GLA, DLGA, AA, and AdrA ( Table 2) .
Meta-Analysis of GWAS of n6 Fatty Acids
LA was associated with multiple SNPs on chromosome 10 in a region that included nuclear receptor-binding factor 2 (NRBF2), jumonji domain containing 1C (JMJD1c), and receptor accessory protein 3 (REEP3; Figure 3A ). The most significant SNP was rs10740118 (P=8.1×10 -9 ). There was no association of SNPs in this region with the other n6 fatty acids. We found the most significant associations of SNP rs174547 in FADS1 on chromosome 11 with all 5 n6 fatty acids. Several other SNPs were also genome-wide significant, falling within the FADS2 and FADS3 regions. Four n6 fatty acids (LA, GLA, DGLA, and AA) were associated with SNPs in a region of chromosome 16 that included pyridoxal-dependent decarboxylase domain containing 1 (PDXDC1), N-terminal asparagine amidase (NTAN1), and RNA polymerase I-specific transcription initiation factor (RRN3). Using LA as an example, Figure 3 shows regional association plots for the 3 identified regions.
Notably, in the 5 cohorts, the top SNP rs174547 on chromosome 11 independently explained a relatively large proportion of variation in certain n6 PUFA, for example, 8.7% to 11.1% for DGLA across the 5 cohorts, and >20% for AA in 4 of the 5 cohorts. rs16966952 on chromosome 16 independently explained 0.1% to 0.6% to 2.0% to 4.5% of total variation in AA and DGLA, respectively; and rs10740118 on chromosome 10 independently explained 0.2 to 0.7% of variation in LA (Table 2 ). These 3 SNPs were genotyped in 4 of the 5 cohorts except CHS, in which the imputation R 2 was 0.80 for rs10740118, and >0.98 for the other 2 SNPs. Forest plots ( Figure I ; Table II in the Data Supplement) were shown for associations between each SNP and LA, and the plots for other n6 fatty acids were similar.
Large numbers of SNPs reached genome-wide significance in each of the 3 identified regions. To identify potential secondary signals within these regions, we conducted conditional analysis for each of the 5 n6 PUFA by adjusting for the top SNP in addition to the covariates included in the main analysis ( Table 2; Tables III-VII in the Data Supplement) . For LA, no other significant association on chromosome 10 was evident after adjustment for the top SNP (rs10740118). Similarly, after adjustment for rs174547, no additional significant association was observed for GLA or AdrA in the region of chromosome 11. Interestingly, after adjusting for rs174547, additional significant associations were identified for LA (rs2727270; P=2.6×10 −21 ), DGLA (rs968567; P=1.3×10 −42 ), and AA (rs102275; P=6.6×10 −147 ). In the region of chromosome 16, we observed no additional significant associations with GLA or AA after adjusting for the top SNP rs16966952. However, in analyses adjusted for rs16966952, another SNP (rs228018) was identified that was significantly associated with LA and DGLA (P=3.6×10 −14 and 4.5×10 −25 ) .
Circulating levels of the 5 n6 PUFA were correlated with each other, with correlation coefficients ranging from −0.63 to 0.49 ( Table VIII in the Data Supplement). In analyses of GLA adjusted for its precursor LA, estimated effect sizes of the most significant SNPs (rs174547 and rs16966952) in the main unadjusted analysis decreased by 47% and 31%, respectively (Table 3) ; rs174547 was still genome-wide significant (P=1.5×10 −20 ), but rs16966952 failed to reach genome-wide significance (P=3.1×10 −6 ; Table 3 ). This observation is consistent with the finding that SNP-LA associations partially explained SNP-GLA associations. Similarly, in analyses of AdrA adjusted for AA, no genome-wide significant signal was observed on chromosome 11 for AdrA (P=2.0×10 −2 for rs174547).
Another motivation for the exploratory analyses was the possibility of discovering new associations: When 2 fatty acids are positively correlated, there is greater statistical power to identify SNP-fatty acid associations that are in the opposite directions for the fatty acid and its precursor. Indeed, in analyses of DGLA adjusted for its precursor GLA, and in analyses of AA adjusted for its precursor DGLA, the rs174547-DGLA and rs16966952-AA associations became more significant (with greater effect sizes; Table 3 ). Furthermore, in analyses of AdrA adjusted for AA, a novel region on chromosome 6 was found. The most significant SNP, rs3134950 (P=2.1×10 −10 ), was positively associated with AA (coefficient=0.085; P=6.6×10 −3 ) but inversely associated with AdrA (coefficient=−0.0097; P=5.7×10 −6 ) in the main analyses. Multiple genes were near the association signals on chromosome 6, including 1-acylglycerol-3-phosphate O-acyltransferase 1 (AGPAT1; Figure 4 ).
Each of the identified significant SNPs was either directly genotyped or imputed with high-quality scores in the 5 cohorts, with the mean imputation quality score (r 2 ) between 0.93 and 1.00. We further examined the potential effect modification of obesity on fatty acid metabolism in the ARIC cohort, the study with the largest sample (n=3269), using body mass index (BMI) information categorized into normal weight (BMI<25), overweight (25<BMI<30), and obese (BMI>30). There was no significant interaction observed between the BMI categories and any of our top SNPs (all P>0.10). Finally, to investigate the potential effect of BMI, physical activity, and dietary intakes of total calories and LA on the study results, we conducted additional analyses using ARIC data. There was little change in the estimated coefficients and P values with or without these covariates in the models and no new signal reached genome-wide significance in the 5 GWASs. We included the estimated effect sizes of the top 3 SNPs in the main analysis in Table IX in the Data Supplement .
Discussion
With ≥8900 adults of European ancestry across 5 prospective cohorts, the present analysis represents the largest GWAS of circulating n6 fatty acids to date. We confirmed previous findings that the FADS cluster on chromosome 11 associates with LA and AA, [18] [19] [20] [21] [22] and further extended these findings to additional n6 PUFAs. In addition, we identified multiple novel regions on chromosomes 6, 10, and 16 with multiple n6 PUFAs.
FADS1 and FADS2 genetic variants play a clear role in regulating n6 PUFAs. In particular, the C allele of rs174547 in FADS1 was associated with a higher proportion of LA and lower GLA (consistent with lower δ-6 desaturase activity) and a higher proportion of DGLA and lower AA (consistent with lower δ-5 desaturase activity). This polymorphism has previously been recognized for its association with n6 PUFAs and desaturase activities, 22 and our findings build on and extend these previous observations by documenting additional inverse associations with GLA and DGLA. Conditional analysis identified additional SNPs in FADS2 associated with higher LA and DGLA and a site upstream from FADS1 associated with lower AA. Together, the data suggest that FADS gene minor allele polymorphisms in FADS1 and FADS2 may suppress δ-5 and δ-6 desaturase expression and activity resulting in less flux through the pathway and lower rates of AA and AdrA syntheses. It remains unclear whether such FADS polymorphisms have biological effects on plasma FA composition, [40] [41] [42] [43] and our findings highlight the need for additional study of potential interaction among FADS variation, n6 PUFAs, and metabolic biomarkers and health outcomes.
Furthermore, rs174547 was highly correlated with rs174538 (r 2 =0.83) in the current study, which was the SNP most significantly associated with n3 FA in our previous GWAS. 17 The 18-carbon N3 fatty acid α-linolenic acid is converted to the 20-and 22-carbon N3 fatty acids (eg, eicosapentaenoic acid and docosahexaenoic acid) via the same enzymatic pathway that converts the 18-carbon LA to the longer chain N6 fatty acids. Therefore, our identification of highly correlated SNPs in the FADS1/2 cluster that relate to both N3 and N6 fatty acids is consistent with existing biochemical knowledge and highlight the important inter-related nature of N3/N6 PUFA metabolism.
Apart from our novel findings for the FADS gene cluster, additional novel associations were observed among multiple n6 PUFAs and gene variants of NRBF2, PDXDC1, AGPAT1, and NTAN1. Notably, all genes except PDXDC1 encode proteins shown to be involved in fatty acid metabolism, which may account for the associations found here. For example, NRBF2 encodes nuclear receptor-binding factor 2 that interacts with peroxisome proliferator activated receptor-α 44 -a transcription factor that upregulates lipoprotein lipase activity and fatty acid oxidation. Although the specific mechanism that accounts for the association between the rs10740118 NRBF2 variant and LA is not established, we hypothesize that variants of nuclear receptorbinding factor 2 may differentially bind peroxisome proliferator activated receptor-α, thus affecting fatty acid bioavailability. Our novel findings indicate the need for additional studies of how NRBF2 influences fatty acid biology and LA in particular.
For AGPAT1 on chromosome 6, we observed an association of the rs3134950 SNP and AdrA, after adjustment for its fatty acid precursor, AA. The AGPAT1-encoded protein, 1-acyl-snglycerol-3-phosphate acyltransferase α, is a critical enzyme in phospholipid and triglyceride biosynthesis, catalyzing the conversion of lysophosphatidic acid to phosphatidic acid. 45 In experimental studies, the AGPAT1 protein shows a preference for LA as a fatty acid substrate. 46 Although AdrA was not investigated as a possible substrate of AGPAT1, our findings suggest the possibility that variation in the AGPAT1 gene may influence the availability of LA and fatty acids downstream in the pathway.
An additional novel finding was the association of genetic variants in NTAN1 on chromosome 16 with lower proportions of all n6 fatty acids except AdrA. Notably, the most significant genetic variant in NTAN1 (rs16966952) is in linkage disequilibrium (r 2 =0.76) with SNP (rs4985167) of the PDXDC1 gene that we previously found to be associated with the n3 fatty acid, α-LA (18:3n3). 17 Biochemically, the PDXDC1-encoded ¶The signal on chromosome 11 was significant in main analysis of AdrA, but nonsignificant when the top SNPs or preceding FA being adjusted; the signal on chromosome 6 became genome-wide significant when preceding FA was adjusted in the model. Figure 3 . A-C, Regional association plots in the genome-wide association of linoleic acid (18:2n6). The color scheme is red for strong linkage disequilibrium (LD) and fading color for lower LD. A, Regional association plot for rs10740118 on chromosome 10. B, Regional association plot for rs174547 on chromosome 11. C, Regional association plot for rs16966952 on chromosome 16. protein is a vitamin B6-dependent decarboxylase that is preferentially expressed in the intestine, but its physiological importance remains unknown. Alternatively, the associated SNPs on chromosome 16 are also proximate to the PLA2G10 gene, which encodes the secretory phospholipase group-10 enzyme (X-sPLA2). Functionally, X-sPLA2 hydrolyzes phospholipids to release free fatty acids 47 and promotes the liberation and bioavailability of n6 AA from glycerophospholipids. 48 Notably, the above findings in the PDXDC1 and PLA2G10 genes are in agreement with a previous report of associations of both genes with phospholipid fatty acid species. 49 Overall, the mechanisms that explain the novel associations of NRBF2 rs10740118, NTAN1 rs16966952, and AGPAT1 SNP rs3134950 with these n6 PUFAs are not completely understood at present but may be because of the corresponding enzyme/protein's role in n6 fatty acid metabolism. Additional research is warranted to explain these associations fully.
The FADS gene polymorphisms have been associated with lipid and cholesterol levels, as well as incident coronary heart disease. In a study of 4635 Swedish subjects, the rs174547 C allele was found to be associated with modestly lower low-density lipoprotein-cholesterol levels but not with highdensity lipoprotein-cholesterol or triglyceride levels in individuals with relatively lower N3 dietary intake. 40 In contrast, a case-control study of coronary heart disease in Chinese subjects revealed that the CC variant of rs174547 was associated with higher high-density lipoprotein-cholesterol and triglyceride levels. 41 The investigators proposed that these variations in lipid levels may be partially attributable to the FADS variant, which may contribute to coronary heart disease development. Finally, a candidate gene case-control study of coronary artery disease reported that certain FADS haplotypes were associated with disease risk. 42 Contrary to these studies, null findings have also been reported in the cohorts of the Nurses' Health Study (n=1200) and the Health Professionals Follow-Up Study (n=1295). 43 It remains important to identify the relationship(s) between SNPs and lipid traits, which improve our biological understanding of these pathways. Furthermore, studies are needed to investigate the association of the new genes with the intermediate end points, such as leukotrienes, thromboxanes, and lipoxins, and with disease outcomes. The current study highlights the unique strength of nonhypothesis-driven GWAS for identifying novel common genetic polymorphisms associated with n6 PUFAs. Using samples with European ancestry from each cohort, as well as including factors for population stratification using principal components analysis, reduces the potential for confounding by population stratification. The meta-analysis approach combines results from multiple cohorts to increase the statistical power to identify genes that may not have been identified because of small effects or low frequency. Importantly, our meta-analysis results were consistent across all participating cohorts ( Figure I in the Data Supplement), further increasing confidence in the validity and generalizability of the findings.
Potential limitations may be considered. First, InCHIANTI examined total plasma fatty acid composition, whereas the other cohorts examined the composition of phospholipid fatty acid fraction. Yet, findings from InCHIANTI were similar to those observed in the other cohorts. Both the magnitude and the direction of associations were consistent across all 5 cohorts ( Figure I in the Data Supplement). We also performed meta-analysis excluding the InCHIANTI study. Notably, the observed associations on chromosomes 10, 11, and 16 were weaker but still consistent (data not shown), which suggests that the tissue where fatty acids were measured had minimal effects on the identified SNP-fatty acid associations. Second, it is possible that environmental factors may influence the gene-fatty acid associations. However, the fatty acid-SNP associations changed little when including BMI, physical activity, and dietary LA and energy intakes in the statistical models using ARIC data ( Table IX in the  Data Supplement) . Third, it must be acknowledged that the present analysis is a hypothesis0generating study. Although we have speculated on potential mechanisms, additional research is required to elucidate the biological effects of the identified polymorphisms. In addition, because of the high linkage disequilibrium in identified loci, it is unclear which SNPs are causal with the associated FA, and finer mapping of these regions is needed to identify the functional SNP. Finally, although our findings passed stringent thresholds for multiple testing corrections, additional replication studies are still needed to confirm our results in other European populations and other cohorts of different racial groups.
Our study confirmed previous GWAS findings that FADS gene variants are associated with plasma and cell membrane fatty acid composition for n6 fatty acids. Notably, we identified novel associations between N6 PUFAs and SNPs in NTAN1, AGPAT1, and NRBF2 genes. Our findings provide a roadmap for further investigation of genetic and metabolic pathways that may influence N6 PUFA.
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